Results from the phase III NRG Oncology GOG-0263 trial—which tested the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for patients with early-stage, intermediate-risk cervical carcinoma—indicated that the addition of chemotherapy did not improve outcomes for patients and led to increased toxicity. The outcomes of this trial support the use of the current standard of care—adjuvant radiotherapy alone after surgery—for this patient population. These results were presented by Ryu et al during the Plenary Session of the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer.
“Despite the negative outcome of this study for improving recurrence-free survival in this population, there are still key takeaways we can learn from to help redirect future research,” stated lead author Sang Young Ryu, MD, of the Department of Gynecologic Oncology at the Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences.
More on NRG-GOG-0263
NRG-GOG-0263 did not meet its primary objective of improving recurrence-free survival through the addition of cisplatin. The trial accrued 316 eligible patients with early-stage disease and intermediate-risk factors, including a combination of histopathologic factors such as capillary lymphatic space involvement, stromal invasion, and tumor size. Accrued patients had undergone radical hysterectomy prior to enrollment onto the study. Trial participants were randomly assigned to receive either adjuvant chemoradiotherapy (CRT) or radiotherapy alone (RT).
A total of 92% of patients received 28 fractions of radiation, with a median dosage of 50.4 Gy and a duration of 39 days, and 91% of the patients in CRT arm received at least four cycles of weekly cisplatin. The 3-year recurrence-free survival estimates for the CRT and RT arms were 88.5% (95% confidence interval [CI] = 82%–93%) and 85.4% (95% CI = 79%–90%). The recurrence-free survival hazard ratio estimate for CRT vs RT was 0.7 (95% CI = 0.4–1.2, P = .09). The estimated overall survival hazard ratio for the CRT vs RT arm was 0.6 (95% CI = 0.2–1.2, P = .07). Grade 3 or 4 adverse events occurred in 15% and 43% of patients in the RT and CRT, arms respectively (P < .0001).
“At this time, women with early-stage [cervical cancer] and intermediate-risk factors are treated with radiotherapy alone. Chemotherapy has been considered as an addition to this treatment, based on prior clinical data indicating it could potentially improve outcomes for these women. The outcomes of this trial help confirm that cisplatin chemotherapy given adjuvantly with radiotherapy is not a superior alternative. Future research needs to elaborate whether the timing of chemotherapy can improve outcomes, or if another alternative can be considered to help improve on the results of this trial while limiting toxicity,” Dr. Ryu added.
Disclosure: This study was supported by the National Cancer Institute (NCI) and was supported by grants U10CA180822 (NRG Oncology SDMC) and U10CA180868 (NRG Oncology Operations) from the NCI.
